BACKGROUND: Fibric acid derivatives and HMG-CoA reductase inhibitors are effective in combination for treating patients with familial dysbetalipoproteinaemia and severe combined dyslipidaemia, but combination therapy affects compliance and increases the risk of side effects. AIM: To evaluate the efficacy and safety of monotherapy with atorvastatin, an HMG-CoA reductase inhibitor with superior efficacy in lowering low density lipoprotein cholesterol and triglyceride concentrations, in patients with dysbetalipoproteinaemia and severe combined dyslipidaemia. METHODS: Atorvastatin was tested as single drug treatment in 36 patients with familial dysbetalipoproteinaemia and 23 patients with severe combined dyslipidaemia. RESULTS: After 40 weeks of 40 mg atorvastatin treatment decreases in total cholesterol, triglycerides, and apolipoprotein B of 40%, 43%, and 41%, respectively, were observed in the combined dyslipidaemia group, and of 46%, 40%, and 43% in the dysbetalipoproteinaemic patients. Target concentrations of total cholesterol (< 5 mmol/l) were reached by 63% of the patients, and target concentrations of triglycerides (< 3.0 mmol/l) by 66%. Treatment with atorvastatin was well tolerated and no serious side effects were reported. CONCLUSIONS: Atorvastatin is very effective as monotherapy in the treatment of familial dysbetalipoproteinaemia and severe combined dyslipidaemia.
BACKGROUND:Fibric acid derivatives and HMG-CoA reductase inhibitors are effective in combination for treating patients with familial dysbetalipoproteinaemia and severe combined dyslipidaemia, but combination therapy affects compliance and increases the risk of side effects. AIM: To evaluate the efficacy and safety of monotherapy with atorvastatin, an HMG-CoA reductase inhibitor with superior efficacy in lowering low density lipoprotein cholesterol and triglyceride concentrations, in patients with dysbetalipoproteinaemia and severe combined dyslipidaemia. METHODS:Atorvastatin was tested as single drug treatment in 36 patients with familial dysbetalipoproteinaemia and 23 patients with severe combined dyslipidaemia. RESULTS: After 40 weeks of 40 mg atorvastatin treatment decreases in total cholesterol, triglycerides, and apolipoprotein B of 40%, 43%, and 41%, respectively, were observed in the combined dyslipidaemia group, and of 46%, 40%, and 43% in the dysbetalipoproteinaemic patients. Target concentrations of total cholesterol (< 5 mmol/l) were reached by 63% of the patients, and target concentrations of triglycerides (< 3.0 mmol/l) by 66%. Treatment with atorvastatin was well tolerated and no serious side effects were reported. CONCLUSIONS:Atorvastatin is very effective as monotherapy in the treatment of familial dysbetalipoproteinaemia and severe combined dyslipidaemia.
Authors: G Utermann; K H Vogelberg; A Steinmetz; W Schoenborn; N Pruin; M Jaeschke; M Hees; H Canzler Journal: Clin Genet Date: 1979-01 Impact factor: 4.438
Authors: W J Schneider; P T Kovanen; M S Brown; J L Goldstein; G Utermann; W Weber; R J Havel; L Kotite; J P Kane; T L Innerarity; R W Mahley Journal: J Clin Invest Date: 1981-10 Impact factor: 14.808
Authors: Moneeza K Siddiqui; Cyrielle Maroteau; Abirami Veluchamy; Aleksi Tornio; Roger Tavendale; Fiona Carr; Ngu-Uma Abelega; Dan Carr; Katyrzyna Bloch; Par Hallberg; Qun-Ying Yue; Ewan R Pearson; Helen M Colhoun; Andrew D Morris; Eleanor Dow; Jacob George; Munir Pirmohamed; Paul M Ridker; Alex S F Doney; Ana Alfirevic; Mia Wadelius; Anke-Hilse Maitland-van der Zee; Daniel I Chasman; Colin N A Palmer Journal: Eur Heart J Date: 2017-12-21 Impact factor: 35.855